SBIO
ALPS Medical Breakthroughs ETF [SBIO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SBIO Stock Summary
Top 10 Correlated ETFs
SBIO
Top 10 Correlated Stocks
SBIO
In the News
SBIO Financial details
Company Rating
-
Market Cap
113.77M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
0.07
Dividend %
0.21%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
12.67%
SMA50
7.84%
SMA100
-0.35%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
23.21-38.8
52W High
-18.61%
52W Low
+34.48%
RSI
59.59
Rel Volume
0.79
Avg Volume
12.97K
Volume
10.22K
Perf Week
0%
Perf Month
4.35%
Perf Quarter
-10.11%
Perf Half Y
-18.15%
-
-
-
-
Beta
0.83
-
-
Volatility
0.27%, 1.45%
Prev Close
-1.12%
Price
30.93
Change
-0.42%
SBIO Financial Performance
SBIO Frequently Asked Questions
What is ALPS Medical Breakthroughs ETF stock symbol ?
ALPS Medical Breakthroughs ETF is a US stock and trading under the symbol SBIO
What is ALPS Medical Breakthroughs ETF stock quote today ?
ALPS Medical Breakthroughs ETF stock price is $30.93 today.
Is ALPS Medical Breakthroughs ETF stock public?
Yes, ALPS Medical Breakthroughs ETF is a publicly traded company.
Company Profile
- Volume Average 12.97K
- Market Capitalization 113.77M
- Headquarters US
- IPO Date 2014-12-31
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
